ncbi.nlm.nih.gov
Above link reference is from Pharmos Israel labs, mice models of multiple sclerosis treatment with dexanabinol.
Nice study, nice results, but long run from mice to humans, in the case of dexanabinol a little less so, because there will not be any need for a phase I study due to plenty of data on safety, straight to phase II.
Probably PARS will not undertake this unless a partner provides the money. If they are strong about trauma indication they will wait for approval first and then is cheaper to do any other indication (stroke, colitis, sepsis, antitoxin, birth asphyxia, multiple sclerosis, Alzheimer's, Parkinson's, and many other chronic nervous system degenerations).
Trauma indication if succesful will make Pharmos bigger than Biogen.
Position: long until recent run up, out a little early at nice profit. I am waiting for cohort 3 of phase II results before I take another position. Stock is fully value for the eye business, not at discount anymore, unless cohort3phaseII give strong indication of benefit. |
